|
1
|
Malats N and Real FX: Epidemiology of
bladder cancer. Hematol Oncol Clin North Am. 29:177–189. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kaufman DS, Shipley WU and Feldman AS:
Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hurst C, Rosenberg J and Knowles M:
SnapShot: Bladder cancer. Cancer Cell. 34:350 e12018. View Article : Google Scholar
|
|
5
|
Stetler-Stevenson WG: The tumor
microenvironment: The connective tissue/tumor cell/host organ
system that modulates tumor progression. Connect Tissue Res.
56:343–344. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fridman WH, Pages F, Sautes-Fridman C and
Galon J: The immune contexture in human tumours: Impact on clinical
outcome. Nat Rev Cancer. 12:298–306. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zitvogel L, Galluzzi L, Smyth MJ and
Kroemer G: Mechanism of action of conventional and targeted
anticancer therapies: Reinstating immunosurveillance. Immunity.
39:74–88. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Branchoux S, Bellera C, Italiano A,
Rustand D, Gaudin AF and Rondeau V: Immune-checkpoint inhibitors
and candidate surrogate endpoints for overall survival across
tumour types a systematic literature review. Crit Rev Oncol
Hematol. 137:35–42. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ottaviano M, De Placido S and Ascierto PA:
Recent success and limitations of immune checkpoint inhibitors for
cancer: A lesson from melanoma. Virchows Arch. 474:421–432. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PDL1 antibody in patients with advanced
cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gnjatic S, Bronte V, Brunet LR, Butler MO,
Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN,
et al: Identifying baseline immune-related biomarkers to predict
clinical outcome of immunotherapy. J Immunother Cancer. 5:442017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Masson-Lecomte A, Rava M, Real FX,
Hartmann A, Allory Y and Malats N: Inflammatory biomarkers and
bladder cancer prognosis: A systematic review. Eur Urol.
66:1078–1091. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kawai K, Miyazaki J, Joraku A, Nishiyama H
and Akaza H: Bacillus Calmette-Guerin (BCG) immunotherapy for
bladder cancer: Current understanding and perspectives on
engineered BCG vaccine. Cancer Sci. 104:22–27. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim J: Immune checkpoint blockade therapy
for bladder cancer treatment. Investig Clin Urol. 57 (Suppl
1):S98–S105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Siska PJ, Johnpulle RAN, Zhou A, Bordeaux
J, Kim JY, Dabbas B, Dakappagari N, Rathmell JC, Rathmell WK,
Morgans AK, et al: Deep exploration of the immune infiltrate and
outcome prediction in testicular cancer by quantitative multiplexed
immunohistochemistry and gene expression profiling. Oncoimmunology.
6:e13055352017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Newman AM, Liu CL, Green MR, Gentles AJ,
Feng W, Xu Y, Hoang CD, Diehn M and Alizadeh AA: Robust enumeration
of cell subsets from tissue expression profiles. Nat Methods.
12:453–457. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu X, Wu S, Yang Y, Zhao M, Zhu G and Hou
Z: The prognostic landscape of tumor-infiltrating immune cell and
immunomodulators in lung cancer. Biomed Pharmacother. 95:55–61.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xiong Y, Wang K, Zhou H, Peng L, You W and
Fu Z: Profiles of immune infiltration in colorectal cancer and
their clinical significant: A gene expression-based study. Cancer
Med. 7:4496–4508. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ali HR, Chlon L, Pharoah PD, Markowetz F
and Caldas C: Patterns of immune infiltration in breast cancer and
their clinical implications: A gene-expression-based retrospective
study. PLoS Med. 13:e10021942016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He Y, Jiang Z, Chen C and Wang X:
Classification of triple-negative breast cancers based on
Immunogenomic profiling. J Exp Clin Cancer Res. 37:3272018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hänzelmann S, Castelo R and Guinney J:
GSVA: Gene set variation analysis for microarray and RNA-seq data.
BMC Bioinformatics. 14:72013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yoshihara K, Shahmoradgoli M, Martínez E
Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW,
Levine DA, et al: Inferring tumour purity and stromal and immune
cell admixture from expression data. Nat Commun. 4:26122013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rooney MS, Shukla SA, Wu CJ, Getz G and
Hacohen N: Molecular and genetic properties of tumors associated
with local immune cytolytic activity. Cell. 160:48–61. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pathria P, Louis TL and Varner JA:
Targeting tumor-associated macrophages in cancer. Trends Immunol.
40:310–327. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chanmee T, Ontong P, Konno K and Itano N:
Tumor-associated macrophages as major players in the tumor
microenvironment. Cancers (Basel). 6:1670–1690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Binnemars-Postma K, Storm G and Prakash J:
Nanomedicine strategies to target tumor-associated macrophages. Int
J Mol Sci. 18:9792017. View Article : Google Scholar
|
|
28
|
Ascierto PA, Capone M, Urba WJ, Bifulco
CB, Botti G, Lugli A, Marincola FM, Ciliberto G, Galon J and Fox
BA: The additional facet of immunoscore: Immunoprofiling as a
possible predictive tool for cancer treatment. J Transl Med.
11:542013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lipponen PK, Eskelinen MJ, Jauhiainen K,
Harju E and Terho R: Tumour infiltrating lymphocytes as an
independent prognostic factor in transitional cell bladder cancer.
Eur J Cancer 29A. 69–75. 1992.
|
|
30
|
Horn T, Laus J, Seitz AK, Maurer T, Schmid
SC, Wolf P, Haller B, Winkler M, Retz M, Nawroth R, et al: The
prognostic effect of tumour-infiltrating lymphocytic subpopulations
in bladder cancer. World J Urol. 34:181–187. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang B, Pan W, Yang M, Yang W, He W, Chen
X, Bi J, Jiang N, Huang J and Lin T: Programmed death ligand-1 is
associated with tumor infiltrating lymphocytes and poorer survival
in urothelial cell carcinoma of the bladder. Cancer Sci.
10:489–498. 2019. View Article : Google Scholar
|
|
32
|
Baras AS, Drake C, Liu JJ, Gandhi N, Kates
M, Hoque MO, Meeker A, Hahn N, Taube JM, Schoenberg MP, et al: The
ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated
with response to cisplatin-based neoadjuvant chemotherapy in
patients with muscle invasive urothelial carcinoma of the bladder.
Oncoimmunology. 5:e11344122016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pahl J and Cerwenka A: Tricking the
balance: NK cells in anti-cancer immunity. Immunobiology.
222:11–20. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Crouse J, Xu HC, Lang PA and Oxenius A: NK
cells regulating T cell responses: Mechanisms and outcome. Trends
Immunol. 1:49–58. 2015. View Article : Google Scholar
|
|
35
|
Jaigirdar SA and MacLeod MK: Development
and function of protective and pathologic memory CD4 T cells. Front
Immunol. 6:4562015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tran Janco JM, Lamichhane P, Karyampudi L
and Knutson KL: Tumor-infiltrating dendritic cells in cancer
pathogenesis. J Immunol. 194:2985–2991. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Darvin P, Toor SM, Sasidharan Nair V and
Elkord E: Immune checkpoint inhibitors: Recent progress and
potential biomarkers. Exp Mol Med. 50:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
